Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 15 May 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The timing of revenue recognition is expected to shift to the next fiscal year following the review of the sales timing for the Cellution centrifuge. The Company is also recording development costs associated with the launch of the CrymEX business in the current fiscal year.
| Item | Details |
|---|---|
| Net Sales | ¥1,060 million → ¥50 million（△95.2％） |
| Operating profit | ¥-123 million → ¥-910 million |
| Ordinary income | ¥-138 million → ¥-920 million |
| Profit attributable to owners of the parent | ¥71 million → ¥-300 million |
| Net income per share | 8.04 yen and sen → -33.6 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 May 2025 |
| Previous-period results | Revenue: ¥122 million; operating loss: ¥806 million; ordinary loss: ¥864 million; net loss attributable to owners of the parent: ¥2,140 million; loss per share: ¥354.86 (fiscal year ended March 2025) |
| Reason for the revision | The timing of revenue recognition is expected to shift to the next fiscal year following the review of the sales timing for the Cellution centrifuge. The Company is also recording development costs associated with the launch of the CrymEX business in the current fiscal year. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the subsidiary's main medical device, the Cellution centrifuge, the Company reviewed the sales timing after prioritizing final adjustments associated with the transition to mass production, measures to address global semiconductor supply constraints, and quality assurance. Delivery from the contract manufacturer is scheduled for August 2026, and revenue is expected to be recognized in the next fiscal year. The Company is also recording development costs associated with the launch of the CrymEX business in the current fiscal year.